张梅庆
【摘要】 目的:探讨生脉饮注射液联合XELOX方案治疗结直肠癌的临床疗效及对患者免疫功能和VEGF的影响。方法:选取2015年1月-2017年1月本院收治的结直肠癌患者80例,按照随机数字表法将其分为观察组和对照组,各40例。对照组给予XELOX方案(卡培他滨+奥沙利铂)治疗,观察组在对照组基础上联合生脉饮注射液治疗。比较两组临床疗效、血管内皮生长因子(VEGF)及免疫功能(CD3+、CD4+、CD8+)水平。结果:观察组总有效率为47.50%,高于对照组的20.00%(P<0.05);治疗后,观察组CD3+、CD4+水平均高于对照组,CD8+、VEGF水平低于对照组,比较差异均有统计学意义(P<0.05)。结论:生脉饮注射液联合XELOX方案治疗结直肠癌有确切疗效,可以降低VEGF水平,并提高患者免疫功能,可推广于临床。
【关键词】 血管内皮生长因子; 免疫功能; 结直肠癌; XELOX方案; 生脉饮注射液; 临床疗效
【Abstract】 Objective:To investigate the clinical efficacy of Shengmaiyin Injection combined with XELOX regimen in treatment of colorectal cancer and its effect on immune function and VEGF.Method:A total of 80 patients with colorectal cancer who admitted to our hospital from January 2015 to January 2017 were selected.According to the random number table method,they were divided into observation group and control group,40 cases in each group.The control group was treated with XELOX regimen(Capecitabine+Oxaliplatin),while observation group was treated with Shengmaiyin Injection on the basis of control group.The clinical efficacy,the levels of vascular endothelial growth factor(VEGF) and immune function(CD3+,CD4+,CD8+) were compared between two groups.Result:The total effective rate of observation group was 47.50%,which was higher than 20.00% of control group(P<0.05).After treatment,the levels of CD3+ and CD4+ in observation group were higher than those of control group,while the levels of CD8+ and VEGF were lower than those of control group,the differences were statistically significant(P<0.05).Conclusion:Shengmaiyin Injection combined with XELOX regimen has a definite curative effect on colorectal cancer,which can reduce the level of VEGF and improve the immune function of patients,which can be extended to the clinic.
【Key words】 Vascular endothelial growth factor; Immune function; Colorectal cancer; XELOX regimen; Shengmaiyin Injection; Clinical efficacy
First-authors address:Xinyu City Hospital of Traditional Chinese Medicine,Xinyu 338000,China
doi:10.3969/j.issn.1674-4985.2018.33.008
结直肠癌是临床常见肿瘤,晚期患者的生存期一般不足6个月[1]。开展全身化疗可以延长患者生存期至9个月,XELOX方案是临床常用抗结直肠癌化疗方案,但应用XELOX方案治疗时不良反应严重,如呕吐、恶心、神经毒性作用,骨髓抑制等[2-3]。生脉饮注射液以五味子、麦冬、红参提取物制成,有解毒、活血、补气之功效,可以提高患者对化疗不良反应的耐受能力[4-5]。本研究应用生脉饮注射液联合XELOX方案治疗结直肠癌,以单纯使用XELOX方案的患者为对照,观察两组疗效、免疫功能及VEGF水平。现报道如下。
1 资料与方法
1.1 一般资料 选取2015年1月-2017年1月本院收治的80例结直肠癌患者为研究对象。纳入标准:根據《结直肠癌诊疗规范(2015年版)》标准诊断为结直肠癌者[6];签署知情同意书者;精神正常,配合治疗,配合随访者;可以给予化疗。排除标准:对生脉饮注射液过敏或因其他原因不宜使用生脉饮注射液者;不宜给予XELOX方案进行化疗者;……